MFN Drug Pricing Fact Sheet (Nov 6, 2025)

https://is1-ssl.mzstatic.com/image/thumb/Podcasts211/v4/4a/8a/e7/4a8ae758-bec2-ea7e-bc29-beb7eb624c48/mza_13183049887170285153.jpeg/600x600bb.jpg

The White House In Audio

Instaread Podcast

1337 episodes

2 days ago

Welcome to "The White House in Audio," your go-to podcast for bringing the latest updates, insights, and stories from the White House blog directly to your ears. Whether you’re on your morning commute or unwinding after a long day, our audio versions of official White House blog articles ensure you stay informed about the policies, events, and initiatives shaping the nation. Join us as we delve into the critical decisions and narratives that impact everyday Americans, narrated with clarity and depth. Stay connected with the heart of the nation's leadership, wherever you are.

Politics

News

RSS

All content for The White House In Audio is the property of Instaread Podcast and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Politics

News

https://d3t3ozftmdmh3i.cloudfront.net/staging/podcast_uploaded_nologo/43008284/d89a8fd40058dc1a.jpg

MFN Drug Pricing Fact Sheet (Nov 6, 2025)

The White House In Audio

4 minutes 18 seconds

2 weeks ago

MFN Drug Pricing Fact Sheet (Nov 6, 2025)

MFN Drug Pricing Fact Sheet (Nov 6, 2025)

MFN agreements: White House announces deals with Eli Lilly and Novo Nordisk to align U.S. prices with lowest peer-nation levels via TrumpRx.
Big GLP‑1 price cuts:
Medicare/Medicaid:
Other drugs (TrumpRx pricing):
Additional terms: MFN pricing guaranteed on all new medicines from Lilly/Novo; repatriation of increased foreign revenue; MFN access for every state Medicaid program.
U.S. manufacturing: Novo Nordisk +$10B (incl. U.S. Wegovy tablet production if approved); Eli Lilly ≥$27B in new U.S. investments.
Rationale: Addresses obesity (CDC adult prevalence ~40%) and chronic disease; argues Americans pay >3× OECD brand-name prices and shoulder ~75% of global pharma profits.
Timeline of actions: EO on MFN pricing (May 12, 2025); manufacturer letters (Jul 31, 2025); five pricing deals announced since Sep 30, 2025.